Compare Sanofi SA (SNY) vs Vanguard Growth Index Fund ETF (VUG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Vanguard Growth Index Fund ETF — how do they compare? Sanofi SA trades at $40.07 (market cap $95.18B), while Vanguard Growth Index Fund ETF trades at $91.97 (market cap $384.60B). The key difference: Vanguard Growth Index Fund ETF is far larger — about 4× Sanofi SA's market cap, and Sanofi SA pays a 6.01% dividend while Vanguard Growth Index Fund ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sanofi SA for 94 Days and Vanguard Growth Index Fund ETF for 47 Days on average.
| SNY | VUG | |
|---|---|---|
Market Cap | $95.18B | $384.60B |
Volume | 2,995,646 | 5,662,307 |
Sector | Health | Sector/Thematic |
52-Week High | $52.34 | $92.64 |
52-Week Low | $39.51 | $70.00 |
Typical Hold Time | 94 Days | 47 Days |
Enterprise Value | $114.48B | — |
Dividend Yield | 6.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sanofi (SNY) trades at $40.23, up 0.07% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong Q2 2026 earnings beat with EPS of $1.21 versus $1.10 expected, continuing a trend of exceeding expectations. Recent expansion of the immunology alliance with Regeneron adds potential for future growth through new antibody programs.
While valuation metrics appear reasonable with P/E of 22.14 and P/S of 1.77, projected 2026 net income decline to $4.0B (8.09% margin) raises concerns. Analyst consensus leans cautious with 44% buy ratings versus 52% hold, suggesting tempered optimism despite recent positive developments.
VUG trades at $91.97, down 0.49% with a bullish technical signal supported by moving averages. The ETF holds dominant positions in mega-cap tech stocks including Nvidia, Apple, and Microsoft, which comprise over 36% of holdings. Recent financial media coverage highlights VUG's historical annual returns averaging 11-12% since its 2004 inception, positioning it as a long-term growth vehicle for investors with multi-decade horizons.
The outlook remains positive for long-term investors seeking growth exposure, though concentration in technology stocks presents sector-specific risks. Current technical levels show support at $89-91 with resistance at $92-94. The neutral oscillator readings suggest potential for consolidation near current levels before further directional movement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Vanguard Growth Index Fund ETF
VUG is an index-based ETF that tracks the CRSP US Large Cap Growth Index, providing concentrated exposure to the largest and fastest-growing companies in the United States. It focuses on stocks with high growth potential across tech, communication, and consumer sectors, serving as a low-cost, high-conviction core holding for long-term capital appreciation.
Read more on VUG →
